Standing Order
Amgen Inc.

Dashboard

Amgen Inc.

AMGNNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$220B
Price$406.0952w $271.18 – $444.12
Conviction5/ 5
Revenue (TTM)$38.1B
Revenue growth YoY+9.2%
P/E (trailing)25.1
Gross margin72.7%
Operating margin33.2%
Net margin22.9%
52w price change+40.8%
Next earningsNov 3, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Aug 13
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Aug 12
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 10
    Ownership changeSEC

    SEC Form 4 insider trading filing reported.

  • Aug 10
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 10
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 7
    Ownership changeSEC

    SEC Form 4 insider transaction filing for Amgen Inc.

  • Aug 7
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 4
    Financial resultsSEC

    Amgen 8-K filed with items 2.02 and 9.01 on financial results.

  • Aug 4
    RegulatoryFDA

    FDA supplemental submission (SUPPL-210) for Neulasta (BLA125031) dated 2026-08-04.

  • Jul 31
    OtherSEC

    Amgen 8-K discloses material cybersecurity incident under Item 1.05.

  • Jul 16
    RegulatoryFDA

    FDA supplemental submission (SUPPL-5202) for NEUPOGEN (BLA103353) filed 2026-07-16.

  • Jun 23
    RegulatoryFDA

    FDA supplemental submission (SUPPL-224) for PROLIA (BLA125320) with status date 2026-06-23.

  • Jun 23
    RegulatoryFDA

    FDA supplemental submission (SUPPL-225) for PROLIA (BLA125320) filed 2026-06-23.

  • Jun 3
    Trial initiationClinicalTrials.gov

    Phase 1/2 TINI 2 trial (NCT05848687) for infant ALL recruiting

  • Jun 2
    DealFederal award

    Amgen awarded $7.29M HHS contract for Nplate kit development incl. ARS indications

    $7M
  • May 29
    Trial initiationClinicalTrials.gov

    Amgen initiates Phase 1 trial (NCT07037758) of Tarlatamab + AB248 in extensive-stage small cell lung cancer; status recruiting.

  • May 21
    OtherSEC

    SEC Form 4 filing reporting change in beneficial ownership.

  • May 21
    OtherSEC

    SEC Form 4 insider ownership filing

  • May 21
    OtherSEC

    Amgen filed SEC Form 4 reporting change in beneficial ownership by insider.

  • May 21
    OtherSEC

    Amgen files SEC Form 4 reporting change in beneficial ownership.

Not financial advice — research and opinion only. Disclosures